当前位置: 首页 >> 检索结果
441. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.
作者: Thomas D Boyer.;Arun J Sanyal.;Florence Wong.;R Todd Frederick.;John R Lake.;Jacqueline G O'Leary.;Daniel Ganger.;Khurram Jamil.;Stephen Chris Pappas.; .
来源: Gastroenterology. 2016年150卷7期1579-1589.e2页
Hepatorenal syndrome type 1 (HRS-1) in patients with cirrhosis and ascites is a functional, potentially reversible, form of acute kidney injury characterized by rapid (<2 wk) and progressive deterioration of renal function. Terlipressin is a synthetic vasopressin analogue that acts, via vascular vasopressin V1 receptors, as a systemic vasoconstrictor. We performed a phase 3 study to evaluate the efficacy and safety of intravenous terlipressin plus albumin vs placebo plus albumin in patients with HRS-1.
442. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
作者: Vlad Ratziu.;Stephen A Harrison.;Sven Francque.;Pierre Bedossa.;Philippe Lehert.;Lawrence Serfaty.;Manuel Romero-Gomez.;Jérôme Boursier.;Manal Abdelmalek.;Steve Caldwell.;Joost Drenth.;Quentin M Anstee.;Dean Hum.;Remy Hanf.;Alice Roudot.;Sophie Megnien.;Bart Staels.;Arun Sanyal.; .
来源: Gastroenterology. 2016年150卷5期1147-1159.e5页
Elafibranor is an agonist of the peroxisome proliferator-activated receptor-α and peroxisome proliferator-activated receptor-δ. Elafibranor improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation. We assessed the safety and efficacy of elafibranor in an international, randomized, double-blind placebo-controlled trial of patients with nonalcoholic steatohepatitis (NASH).
443. A randomised controlled trial of a Mediterranean Dietary Intervention for Adults with Non Alcoholic Fatty Liver Disease (MEDINA): study protocol.
作者: Elena S Papamiltiadous.;Stuart K Roberts.;Amanda J Nicoll.;Marno C Ryan.;Catherine Itsiopoulos.;Agus Salim.;Audrey C Tierney.
来源: BMC Gastroenterol. 2016年16卷14页
Non-alcoholic fatty liver disease, the most prevalent liver disease in developed countries, remains difficult to manage with no proven safe and effective pharmacotherapy available. While weight reduction is the most commonly practiced treatment strategy, this is difficult to both achieve and/or maintain in the majority. Furthermore evidence-based dietary recommendations to guide the nutritional management of these patients are lacking. Using a randomised controlled trial design, this study compares the effectiveness of the Mediterranean diet to a standard low fat diet in terms of differences in insulin sensitivity, hepatic steatosis and metabolic outcomes in participants with non-alcoholic fatty liver disease.
444. Rectal Indomethacin Does Not Prevent Post-ERCP Pancreatitis in Consecutive Patients.
作者: John M Levenick.;Stuart R Gordon.;Linda L Fadden.;L Campbell Levy.;Matthew J Rockacy.;Sarah M Hyder.;Brian E Lacy.;Steven P Bensen.;Douglas D Parr.;Timothy B Gardner.
来源: Gastroenterology. 2016年150卷4期911-7; quiz e19页
Rectal indomethacin, a nonsteroidal anti-inflammatory drug, is given to prevent pancreatitis in high-risk patients undergoing endoscopic retrograde cholangiopancreatography (ERCP), based on findings from clinical trials. The European Society for Gastrointestinal Endoscopy guidelines recently recommended prophylactic rectal indomethacin for all patients undergoing ERCP, including those at average risk for pancreatitis. We performed a randomized controlled trail to investigate the efficacy of this approach.
445. Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis.
作者: Juan G Abraldes.;Candid Villanueva.;Carles Aracil.;Juan Turnes.;Manuel Hernandez-Guerra.;Joan Genesca.;Manuel Rodriguez.;Jose Castellote.;Juan Carlos García-Pagán.;Ferran Torres.;Jose Luis Calleja.;Agustin Albillos.;Jaime Bosch.; .
来源: Gastroenterology. 2016年150卷5期1160-1170.e3页
The combination of β-blockers and band ligation is the standard approach to prevent variceal rebleeding, but bleeding recurs and mortality is high. The lipid-lowering drug simvastatin decreases portal pressure, improves hepatocellular function, and might reduce liver fibrosis. We assessed whether adding simvastatin to standard therapy could reduce rebleeding and death after variceal bleeding in patients with cirrhosis.
446. Intensive Enteral Nutrition Is Ineffective for Patients With Severe Alcoholic Hepatitis Treated With Corticosteroids.
作者: Christophe Moreno.;Pierre Deltenre.;Christelle Senterre.;Alexandre Louvet.;Thierry Gustot.;Boris Bastens.;Axel Hittelet.;Marie-Astrid Piquet.;Wim Laleman.;Hans Orlent.;Luc Lasser.;Thomas Sersté.;Peter Starkel.;Xavier De Koninck.;Sergio Negrin Dastis.;Jean Delwaide.;Isabelle Colle.;Chantal de Galocsy.;Sven Francque.;Philippe Langlet.;Virginie Putzeys.;Hendrik Reynaert.;Delphine Degré.;Eric Trépo.
来源: Gastroenterology. 2016年150卷4期903-10.e8页
Severe alcoholic hepatitis (AH) is a life-threatening disease for which adequate oral nutritional support is recommended. We performed a randomized controlled trial to determine whether the combination of corticosteroid and intensive enteral nutrition therapy is more effective than corticosteroid therapy alone in patients with severe AH.
447. Histamine Receptor H1-Mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome.
作者: Mira M Wouters.;Dafne Balemans.;Sander Van Wanrooy.;James Dooley.;Vincent Cibert-Goton.;Yeranddy A Alpizar.;Eduardo E Valdez-Morales.;Yasmin Nasser.;Paul P Van Veldhoven.;Winde Vanbrabant.;Schalk Van der Merwe.;Raf Mols.;Bart Ghesquière.;Carla Cirillo.;Inge Kortekaas.;Peter Carmeliet.;Willy E Peetermans.;Séverine Vermeire.;Paul Rutgeerts.;Patrick Augustijns.;Peter W Hellings.;Ann Belmans.;Stephen Vanner.;David C Bulmer.;Karel Talavera.;Pieter Vanden Berghe.;Adrian Liston.;Guy E Boeckxstaens.
来源: Gastroenterology. 2016年150卷4期875-87.e9页
Histamine sensitizes the nociceptor transient reporter potential channel V1 (TRPV1) and has been shown to contribute to visceral hypersensitivity in animals. We investigated the role of TRPV1 in irritable bowel syndrome (IBS) and evaluated if an antagonist of histamine receptor H1 (HRH1) could reduce symptoms of patients in a randomized placebo-controlled trial.
448. Design of a dietary intervention to assess the impact of a gluten-free diet in a population with type 1 Diabetes and Celiac Disease.
作者: Esther Assor.;Margaret A Marcon.;Natasha Hamilton.;Marilyn Fry.;Tammy Cooper.;Farid H Mahmud.
来源: BMC Gastroenterol. 2015年15卷181页
Celiac Disease occurs at a 5-10 fold greater prevalence in patients with type-1 diabetes (T1D), despite this increased risk, there is limited objective evidence regarding the impact of a Gluten-Free Diet (GFD) in the large proportion of asymptomatic (30-70%) patients with both autoimmune diseases. Given the requirements and intricacies inherent to each condition, we describe the rationale and design a dietary curriculum specifically addressing the educational requirements for children and adults with CD and diabetes as part of the CD-DIET Study.
449. Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol.
作者: Jennifer E Lambert.;Jill A Parnell.;Bertus Eksteen.;Maitreyi Raman.;Marc R Bomhof.;Kevin P Rioux.;Karen L Madsen.;Raylene A Reimer.
来源: BMC Gastroenterol. 2015年15卷169页
Evidence for the role of the gut microbiome in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) is emerging. Strategies to manipulate the gut microbiota towards a healthier community structure are actively being investigated. Based on their ability to favorably modulate the gut microbiota, prebiotics may provide an inexpensive yet effective dietary treatment for NAFLD. Additionally, prebiotics have established benefits for glucose control and potentially weight control, both advantageous in managing fatty liver disease. Our objective is to evaluate the effects of prebiotic supplementation, adjunct to those achieved with diet-induced weight loss, on heptic injury and liver fat, the gut microbiota, inflammation, glucose tolerance, and satiety in patients with NAFLD.
450. Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis.
作者: Franck Carbonnel.;Jean Frédéric Colombel.;Jérome Filippi.;Konstantinos H Katsanos.;Laurent Peyrin-Biroulet.;Mathieu Allez.;Maria Nachury.;Gottfried Novacek.;Silvio Danese.;Vered Abitbol.;Fabrizio Bossa.;Jacques Moreau.;Gilles Bommelaer.;Arnaud Bourreille.;Mathurin Fumery.;Xavier Roblin.;Walter Reinisch.;Yoram Bouhnik.;Hedia Brixi.;Philippe Seksik.;Georgia Malamut.;Martti Färkkilä.;Baya Coulibaly.;Olivier Dewit.;Edouard Louis.;Dominique Deplanque.;Pierre Michetti.;Hélène Sarter.;David Laharie.; .; .
来源: Gastroenterology. 2016年150卷2期380-8.e4页
Parenteral methotrexate is an effective treatment for patients with Crohn's disease, but has never been adequately evaluated in patients with ulcerative colitis (UC). We conducted a randomized controlled trial to determine its safety and efficacy in patients with steroid-dependent UC.
451. An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active crohn's disease.
作者: Naoki Yoshimura.;Yoko Yokoyama.;Katsuyoshi Matsuoka.;Hiroki Takahashi.;Ryuichi Iwakiri.;Takayuki Yamamoto.;Tomoo Nakagawa.;Takumi Fukuchi.;Satoshi Motoya.;Reiko Kunisaki.;Shingo Kato.;Fumihito Hirai.;Yoh Ishiguro.;Satoshi Tanida.;Sakiko Hiraoka.;Keiichi Mitsuyama.;Shunji Ishihara.;Shinji Tanaka.;Michiro Otaka.;Taro Osada.;Takashi Kagaya.;Yasuo Suzuki.;Hiroshi Nakase.;Hiroyuki Hanai.;Kenji Watanabe.;Nobuhito Kashiwagi.;Toshifumi Hibi.
来源: BMC Gastroenterol. 2015年15卷163页
Granulocyte and monocyte adsorptive apheresis (GMA) has shown efficacy in patients with active Crohn's disease (CD). However, with routine weekly therapy, it may take several weeks to achieve remission. This study was performed to assess clinical efficacy and safety of intensive GMA in patients with active CD.
452. Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women.
作者: Shin Fukudo.;Yoshikazu Kinoshita.;Toshikatsu Okumura.;Motoko Ida.;Hiraku Akiho.;Yoshihiro Nakashima.;Akito Nishida.;Ken Haruma.
来源: Gastroenterology. 2016年150卷2期358-66.e8页
Previous studies have indicated that serotonin-3-receptor antagonists might have a sex-specific effect in patients with irritable bowel syndrome with diarrhea (IBS-D). Alosetron has been approved for the treatment of only women, and ramosetron has been approved for the treatment for only men. We performed a randomized, placebo-controlled, phase 3 study to determine whether ramosetron reduces symptoms of IBS-D in women.
453. Agreement Between Rectosigmoidoscopy and Colonoscopy Analyses of Disease Activity and Healing in Patients With Ulcerative Colitis.
作者: Jean-Frédéric Colombel.;Ingrid Ordás.;Thomas Ullman.;Paul Rutgeerts.;Akiko Chai.;Sharon O'Byrne.;Timothy T Lu.;Julián Panés.
来源: Gastroenterology. 2016年150卷2期389-95.e3页
Endoscopy limited to the rectosigmoid colon is the standard technique used to measure endoscopic healing in ulcerative colitis (UC) clinical trials. We evaluated whether rectosigmoidoscopy adequately measures UC activity in the more proximal colon.
454. Xyloglucan for the treatment of acute diarrhea: results of a randomized, controlled, open-label, parallel group, multicentre, national clinical trial.
作者: Lucio Gnessi.;Vladimir Bacarea.;Marius Marusteri.;Núria Piqué.
来源: BMC Gastroenterol. 2015年15卷153页
There is a strong rationale for the use of agents with film-forming protective properties, like xyloglucan, for the treatment of acute diarrhea. However, few data from clinical trials are available.
455. Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B.
作者: Patrick Marcellin.;Sang Hoon Ahn.;Xiaoli Ma.;Florin A Caruntu.;Won Young Tak.;Magdy Elkashab.;Wan-Long Chuang.;Seng-Gee Lim.;Fehmi Tabak.;Rajiv Mehta.;Joerg Petersen.;Graham R Foster.;Lillian Lou.;Eduardo B Martins.;Phillip Dinh.;Lanjia Lin.;Amoreena Corsa.;Prista Charuworn.;G Mani Subramanian.;Hans Reiser.;Hendrick W Reesink.;Scott Fung.;Simone I Strasser.;Huy Trinh.;Maria Buti.;Giovanni B Gaeta.;Aric J Hui.;George Papatheodoridis.;Robert Flisiak.;Henry L Y Chan.; .
来源: Gastroenterology. 2016年150卷1期134-144.e10页
Patients chronically infected with the hepatitis B virus rarely achieve loss of serum hepatitis B surface antigen (HBsAg) with the standard of care. We evaluated HBsAg loss in patients receiving the combination of tenofovir disoproxil fumarate (TDF) and peginterferon α-2a (peginterferon) for a finite duration in a randomized trial.
456. Aspirin, Calcitriol, and Calcium Do Not Prevent Adenoma Recurrence in a Randomized Controlled Trial.
作者: Hans-Christian Pommergaard.;Jakob Burcharth.;Jacob Rosenberg.;Hans Raskov.
来源: Gastroenterology. 2016年150卷1期114-122.e4页
Chemopreventive strategies might be used to reduce the recurrence of colorectal adenomas and the incidence of colorectal cancer. We performed a randomized, double-blind, placebo-controlled trial to determine whether a combination of acetylsalicylic acid (aspirin), calcitriol, and calcium carbonate could prevent colorectal adenoma recurrence.
457. Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial.
作者: William J Sandborn.;Julian Panés.;Haiying Zhang.;Dahong Yu.;Wojciech Niezychowski.;Chinyu Su.
来源: Gastroenterology. 2016年150卷1期96-102页
Accurate biomarkers of disease activity and therapeutic response can be valuable for clinical trials. We performed a post hoc analysis of data from a phase 2 trial to assess the relationship between the concentration of fecal calprotectin (FCP) and clinical and endoscopic outcomes of patients with moderate to severe ulcerative colitis receiving tofacitinib.
458. Effects of acotiamide on esophageal motor function and gastroesophageal reflux in healthy volunteers.
作者: Norihisa Ishimura.;Mami Mori.;Hironobu Mikami.;Shino Shimura.;Goichi Uno.;Masahito Aimi.;Naoki Oshima.;Shunji Ishihara.;Yoshikazu Kinoshita.
来源: BMC Gastroenterol. 2015年15卷117页
The prevalence of gastroesophageal reflux disease (GERD) has been increasing worldwide, with proton pump inhibitor (PPI) administration the current mainstay therapy for affected individuals. However, PPI efficacy is insufficient especially for non-erosive reflux disease. Although it has been reported that prokinetic drugs improve GERD, their effects on esophageal function remain to be clearly investigated. In the present study, we evaluated the direct effects of acotiamide, a novel prokinetic agent for the treatment of functional dyspepsia, on esophageal motor function and gastroesophageal reflux.
459. Volume, distribution and acidity of gastric secretion on and off proton pump inhibitor treatment: a randomized double-blind controlled study in patients with gastro-esophageal reflux disease (GERD) and healthy subjects.
作者: Andreas Steingoetter.;Matthias Sauter.;Jelena Curcic.;Dian Liu.;Dieter Menne.;Michael Fried.;Mark Fox.;Werner Schwizer.
来源: BMC Gastroenterol. 2015年15卷111页
Postprandial accumulation of gastric secretions in the proximal stomach above the meal adjacent to the esophagogastric junction (EGJ), referred to as the 'acid pocket', has been proposed as a pathophysiological factor in gastro-esophageal reflux disease (GERD) and as a target for GERD treatment. This study assessed the effect of proton pump inhibitor (PPI) therapy on the volume, distribution and acidity of gastric secretions in GERD and healthy subjects (HS).
460. "A randomized, double-blind study of the effects of omega-3 fatty acids (Omegaven) on outcome after major liver resection".
作者: Michael Linecker.;Perparim Limani.;Florin Botea.;Irinel Popescu.;Ruslan Alikhanov.;Michail Efanov.;Pavel Kim.;Igor Khatkov.;Dimitri Aristotele Raptis.;Christoph Tschuor.;Beatrice Beck-Schimmer.;John Bonvini.;Andrea Wirsching.;Philipp Kron.;Ksenija Slankamenac.;Bostjan Humar.;Rolf Graf.;Henrik Petrowsky.;Pierre-Alain Clavien.
来源: BMC Gastroenterol. 2015年15卷102页
The body is dependent on the exogenous supply of omega-3 polyunsaturated fatty acids (n3-PUFA). These essential fatty acids are key players in regulating metabolic signaling but also exert anti-inflammatory and anti-carcinogenic properties. The liver is a major metabolic organ involved in fatty acid metabolism. Under experimental conditions, n3-PUFA exert beneficial effect on hepatic steatosis, regeneration and inflammatory insults such as ischemic injury after surgery. Some of these effects have also been observed in human subjects. However, it is unclear whether perioperative administration of n3-PUFA is sufficient to protect the liver from ischemic injury. Therefore, we designed a randomized controlled trial (RCT) assessing n3-PUFA (pre-) conditioning strategies in patients scheduled for liver surgery.
|